| Comprehensive molecular portraits of human breast tumours Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park ... Nature 490 (7418), 61-70, 2012 | 11665 | 2012 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2279 | 2018 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1575 | 2015 |
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor … NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ... Journal of clinical oncology 29 (10), 1252-1260, 2011 | 1255 | 2011 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 1203 | 2021 |
| The CAG repeat within the androgen receptor gene and its relationship to prostate cancer E Giovannucci, MJ Stampfer, K Krithivas, M Brown, A Brufsky, J Talcott, ... Proceedings of the National Academy of Sciences 94 (7), 3320-3323, 1997 | 1098 | 1997 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1091 | 2018 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 786 | 2020 |
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ... Clinical cancer research 15 (4), 1452-1459, 2009 | 774 | 2009 |
| Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with … S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ... Journal of clinical oncology 26 (10), 1664-1670, 2008 | 673 | 2008 |
| Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus … EH Romond, JH Jeong, P Rastogi, SM Swain, CE Geyer Jr, MS Ewer, ... Journal of Clinical Oncology 30 (31), 3792-3799, 2012 | 604 | 2012 |
| Bevacizumab added to neoadjuvant chemotherapy for breast cancer HD Bear, G Tang, P Rastogi, CE Geyer Jr, A Robidoux, JN Atkins, ... New England Journal of Medicine 366 (4), 310-320, 2012 | 569 | 2012 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 542 | 2021 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138-3149, 2020 | 540 | 2020 |
| Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ... New England journal of medicine 380 (25), 2395-2405, 2019 | 503 | 2019 |
| RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line … AM Brufsky, S Hurvitz, E Perez, R Swamy, V Valero, V O'Neill, HS Rugo Journal of clinical oncology 29 (32), 4286-4293, 2011 | 495 | 2011 |
| Cognitive impairment associated with adjuvant therapy in breast cancer CM Bender, SM Sereika, SL Berga, VG Vogel, AM Brufsky, KK Paraska, ... Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2006 | 460 | 2006 |
| Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial A Robidoux, G Tang, P Rastogi, CE Geyer, CA Azar, JN Atkins, ... The lancet oncology 14 (12), 1183-1192, 2013 | 452 | 2013 |
| Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER AM Brufsky, M Mayer, HS Rugo, PA Kaufman, E Tan-Chiu, D Tripathy, ... Clinical Cancer Research 17 (14), 4834-4843, 2011 | 435 | 2011 |
| TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ... Journal of Clinical Oncology 38 (36), 4274-4282, 2020 | 388 | 2020 |
